Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.
|Podcasts|October 9, 2020
Episode 19: The Vascular Implications of Alzheimer Disease
Author(s)Matt Hoffman
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Costantino Iadecola, MD.
Advertisement
Episode 19 of the NeurologyLive
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 19, "The Vascular Implications of Alzheimer Disease," features an interview with Costantino Iadecola, MD, Anne Titzell Professor of Neurology, and director and chair, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine. He discussed the shortcomings of the current clinical approach to Alzheimer disease and offered insight into how vascular risk factors play a role in its pathology.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis
2
New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease
3
From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy
4
GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease
5